Products and Services for Cell and Gene Therapy –
From Discovery to Commercialization

Therapeutic, serum-free cell-culture media enabling robust, consistent and cost-efficient processes for cell and gene therapies.

Research grade hematopoietic, immune and stem cells with related media, from immediately available cryopreserved cells to made-to-order fresh whole tissue.

The LV Unit expands our proven 4D-Nucleofector^® System to closed, scalable transfection of larger cell numbers in the range of 1x10⁷ to 1x10⁹ cells in research or GMP environments.

An extensive service offering that includes tailored process and analytical development, cGMP manufacturing, and regulatory services.

The Bacterial Endotoxin Test (BET) is a crucial safety requirement for end-product release. Our regulatory compliant BET products and services ensure your cell therapies can be used with confidence.

A configurable and flexible electronic batch record solution for paperless data capture in laboratories and manufacturing facilities with GMP compliance and tracking at its core.

A functionally closed and automated platform for cell therapy manufacturing, providing flexibility and scalability to your process and allowing you to substantially reduce costs.

In this interview Dr. Manon Destalminil, Bioprocessing Project Leader at CellProthera, discusses the advantages of using research-grade CD34+ cells for cell and gene therapy process development.

In this serum-free media case study, learn how selection of memory T cells can aid in streamlining CAR-T therapies.

Watch our team demonstrate the 4D-Nucleofector^® LV Unit for efficient large-scale electroporation and learn about the technology’s benefits for ex vivo genetic modification in cell and gene therapy manufacturing. 

Are you interested in cell and gene therapy research, development or manufacturing? Check out the recorded presentations and the roundtable discussion from our recent European CGT Workshop. Register below to access the recordings. Already registered? Enter your email address here and watch them on demand.

Learn how Lonza’s Cocoon^® Platform, 4D-Nucleofector^® LV Unit and X-VIVO^® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow.

Learn from Senior Scientist Jerome Jacques how Lonza's new TheraPEAK^® SfAAV^® Medium can help to streamline and accelerate the production of AAV in Sf9 cells.

Case study examining how MES Solutions improve operational efficiency and save costs.  MES solutions can remove paper from the manufacturing floor— while boosting operational efficiency and saving costs.

Join leading cell therapy thought leaders as they share their insights and lessons learned on advancing therapies from bench to bedside, the challenges they face, and where in their view the fast-evolving cell therapy field is heading.

Presented by CAR-TCR Digital Week

Learn from our peer-reviewed article, published by Cell & Gene Therapy Insights, how serum-free media can support large-scale, regulatory compliant expansion processes. Download the PDF below or read the article on the publisher's website.

Learn about Lonza's approach digitalizing our cell therapy manufacturing operations and the future plans for the MODA-ES^TM System within Lonza.

Cell and gene therapy are a hot topic, but are you aware of the requirements around endotoxin testing for these products? Here is a short overview.